MB4 / Mustbio, Celltrion - LARVOL DELTA

Redirecting Regioselectivity in Cytochrome P450 ApPT for B-Ring Functionalization of Pentacyclic Triterpenoids. (PubMed, Angew Chem Int Ed Engl) - "Here we report a semi-rationally engineered P450 variant, MB4, that enables highly selective C7β hydroxylation of 18β-glycyrrhetinic acid, achieving C-H activation on the B-ring with > 99% regioselectivity...Biological evaluation showed that several C7-acylated derivatives exhibited antiproliferative activity (IC50 = 0.31-5.04 µM) by triggering caspase-3-dependent apoptosis and inducing G2/M-phase arrest. This work provides a promising blueprint for reprogramming P450 selectivity for late-stage C-H functionalization of polycyclic natural products."

Journal • CASP3

Purification and evaluation of anti-inflammatory and antioxidant properties of an apramycin-like compound from Microbacterium barkeri. (PubMed, Nat Prod Res) - "Thin-layer chromatography of the crude extract yielded six fractions, of which MB4 compound showed the highest antimicrobial activity. Molecular docking studies against IL-1 and IL-18 receptors revealed binding energies of -6.85 kcal/mol and -7.72 kcal/mol, respectively. These results highlight the pharmacological potential of the apramycin-like aminoglycoside compound from Microbacterium barkeri."

Journal • IL18

Dietary Supplementation of Astaxanthin-Enriched Rhodosporidiobolus ruineniae PBMB1 Improves Growth, Immunity, Disease Resistance, and Pigmentation in Shrimp. (PubMed, Dev Comp Immunol) - "This study evaluated the astaxanthin-enriched yeast Rhodosporidiobolus ruineniae PBMB1 as a dietary supplementation at 2% (MB2%), 4% (MB4%), and 6% (MB6%) (wet weight), with a focus on immune-related gene responses...PBMB1 supplementation was also associated with variations in pigmentation and crude protein content as indicators of meat quality across treatments. Overall, the findings suggest that R. ruineniae PBMB1 may contribute to improved shrimp health, potentially through modulation of gene expression related to immune defense and metabolism, supporting its potential application as a functional dietary yeast additive in sustainable shrimp aquaculture."

Journal • Infectious Disease • CAT

A first-in-class αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates promising anti-tumor efficacy in immune checkpoint inhibitor-resistant tumor models (AACR 2025) - "The αPD-1/αVEGF/IL-2v exhibited blocking activity against PD-1/PD-L1 binding comparable to pembrolizumab, showed VEGF/VEGFR blockade activity similar to that of αVEGF antibody, and effectively induced CD8+ T cell activation comparable to aldesleukin...The murine surrogate of αPD-1/αVEGF/IL-2v demonstrated dose-dependent anti-tumor efficacy, superior to αPD-1 or αPD-1/αVEGF bispecific antibody in both ICI-resistant MC38 and B16F10 tumor models without body weight loss. In conclusion, αPD-1/αVEGF/IL-2v represents a first-in-class tri-specific fusion protein with therapeutic potential to overcome the limitations of αPD-1 or αPD-1/αVEGF therapies."

Checkpoint inhibition • Preclinical • Trispecific • Oncology • CD8

Discovery of AM E3: A novel α-TLSPR monoclonal antibody for the ADC treatment of CRLF2-rearranged Ph-like B-ALL (AACR 2024) - "AM E3 is a novel α-TLSPR mAb with ideal features for the development of a first-in-class ADC therapy. α-TLSPR ADC demonstrated in vitro and in vivo efficacy as a monotherapy for the treatment of CRLF2/TLSPR rearranged Ph-like B-ALLs and proven to be well-tolerated in surrogate animal studies."

ADC • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CRLF2

AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL (AACR 2025) - "Moreover, AM E3-SG3249 treatment extended survival of hCRLF2-rearranged B-ALL orthotopic xenografts over standard induction therapy combining vincristine, dexamethasone, and L-asparaginase (VXL). AM E3 is a novel monoclonal antibody with ideal features for the development of a first-in-class α-CRLF2 ADC therapy. AM E3 conjugated with the cytotoxic agent tesirine (SG3249) demonstrated remarkable anti-tumor efficacy and a reasonable therapeutic window for the treatment of CRLF2-rearranged Ph-like B-ALL."

ADC • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CRLF2

Isolation of high yield polyhydroxyalkanoate producing bacteria from contaminated soils and biopolymer characterization. (PubMed, Sci Rep) - "Five strains Paenibacillus lautus (MA2), Alcaligenes pakistanensis (MA3), Acinetobacter baumannii (MB1), Bacillus cereus (MB4), and Bacillus tropicus (MC3) were identified via 16 S rRNA sequencing against the NCBI BLAST database...Proton nuclear magnetic resonance (¹H NMR) confirmed copolymer composition, with 3-hydroxybutyrate signals at δ 1.28 ppm (CH₃), δ 2.56 ppm (CH₂-CO-), and δ 5.25 ppm (-CH-O-); 3-hydroxyvalerate peaks appeared at δ 0.9 ppm (terminal CH₃), δ 1.6-1.8 ppm (CH₂-), and δ 2.4-2.6 ppm (CH₂-CO-). These findings affirm the biopolymers' authenticity and versatility, supporting applications in biomedicine, biotechnology, and sustainable manufacturing."

Journal

A highly TME-selective αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates potent anti-tumor activity beyond αPD-1/αVEGF therapy (SITC 2025) - "Consistent with the in vitro results, αPD-1/αVEGF/IL-2v demonstrated superior anti-tumor efficacy without body weight loss in TKI-resistant lung cancer bearing humanized mice, compared to αPD-1 or αPD-1/αVEGF bsAbs.Conclusions αPD-1/αVEGF/IL-2v is a highly TME-selective tri-specific fusion protein designed to enhance anti-tumor efficacy with favorable tolerability. These preclinical findings suggest that αPD-1/αVEGF/IL-2v holds therapeutic potential as a next-generation immunotherapy capable of overcoming the limitations of current αPD-1 or αPD-1/αVEGF-based therapies."

Trispecific • Lung Cancer • Oncology • Solid Tumor • CD8 • IL2